HQIC Community of Practice Call

Central Line-associated Bloodstream Infection (CLABSI) Control and Reduction During the COVID-19 Pandemic May 12, 2022

This material was prepared by The Bizzell Group (Bizzell), the Data Validation and Administrative (DVA) contractor, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. 12SOW/Bizzell/DVA-0754-4/6/22



Introduction



Shaterra Smith Social Science Research Analyst - Division of Quality Improvement Innovation Models Testing iQuality Improvement and Innovations Group Center for Clinical Standards and Quality CMS

Welcome!

Who's in the Room?



Agenda

- Introduction
- Today's Topic
 - CLABSI Control and Reduction During the COVID-19 Pandemic Presentations by Geoff Granseth and Eli DeLille, Health Services Advisory Group (HSAG)
 Caroline Gill Rifold, CHA Hollywood Presbyterian Medical Center
- Open Discussion
- Closing Remarks



As You Listen, Ponder...

- What information can you leverage to help expand opportunities in your facilities and communities?
- What impactful actions can you take as a result of the information shared today?
- Where can you begin with your facility to continue to ensure safety, and a true patient-centered approach as you engage collaboratively with others?
- What activities do you have underway that will allow for you to expand and push forward in action over the next 30, 60 or 90 days?



Meet Your Speakers



Geoff Granseth, MPH, CIC Quality Advisor Health Services Advisory Group (HSAG) Infection Preventionist ggranseth@hsag.com



Eli DeLille, MSN, RN, CIC, FAPIC Associate Director Health Services Advisory Group (HSAG) Infection Preventionist edelille@hsag.com



Caroline Gill Rifold, RN, BSN Manager, Infection Prevention Infection Prevention & Hospital Epidemiology CHA Hollywood Presbyterian Medical Center



Summary of CLABSI Impact and Cost

- CLABSIs are the **3rd most frequent** cause of Healthcare-Associated Infections (HAIs).¹
- Mortality rates from CLABSI range from 12%–25% and significantly increase cost and hospital length of stay (CDC).¹
- The estimated cost of each CLABSI is **\$48,108**.²



CLABSI = central line-associated bloodstream infection, HAI = healthcare-associated infection, CDC = Centers for Disease Control and Prevention

 Woodward B, Umberger R. Review of Best Practices for CLABSI Prevention and the Impact of Recent Legislation on CLABSI Reporting. Sage. Nov. 2016. <u>https://journals.sagepub.com/doi/pdf/10.1177/2158244016677747</u>
 Agency for Healthcare Research and Quality. Estimating the Additional Hospital Inpatient Cost and Mortality Associated With Selected Hospital-Acquired Conditions. <u>https://www.ahrq.gov/hai/pfp/haccost2017-results.html</u>



Epidemiology of CLABSI

- An estimated 30,100 CLABSIs occur in the United States each year.¹
- CLABSIs are preventable when fundamental infection control practices are followed.



2019 National SIR: 0.689²

- ICU: 0.732
- Ward: 0.672

SIR = standardized infection ratio

2019 National SUR: 0.8753²

- ICU: 0.9105
- Ward: 0.8584

SUR = standardized utilization ratio

1. CDC. NHSN Patient Safety Component Manual. <u>https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf</u> 2. CDC. Current HAI Progress Report. <u>https://www.cdc.gov/hai/data/portal/progress-report.html#2018</u>



The Impact of COVID-19 on HAIs


	2020 Q1	2020 Q1 2020 Q2		2020 Q4	
CLABSI	-11.8%	27.9%	46.4%	1 47.0%	
CAUTI	-21.3%	No Change ¹	12.7%	18.8%	
VAE	11.3%	1 33.7%	1 29.0%	44.8%	
SSI: Colon surgery	-9.1%	No Change ¹	-6.9%	-8.3%	
SSI: Abdominal hysterectomy	-16.0%	No Change ¹	No Change ¹	-13.1%	
Laboratory-identified MRSA bacteremia	-7.2%	12.2%	22.5%	133.8%	
Laboratory-identified CDI	-17.5%	-10.3%	-8.8%	-5.5%	

CAUTI = catheter-associated urinary tract infection, VAE = ventilator-associated event, SSI = surgical site infection, MRSA = Methicillin-resistant Staphylococcus aureus, CDI = Clostridioides difficile infection

The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network | Infection Control & Hospital Epidemiology | Cambridge Core. <u>https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/impact-of-coronavirus-disease-2019-covid19-on-healthcareassociated-infections-in-2020-a-summary-of-data-reported-to-the-national-healthcare-safety-network/8197F323F4840D233A0C62F4726287E1</u>



HSAG HQIC Aggregate: CLABSI SIR—Critical Care



RIR	-119.59%	Baseline R (01/01/2019–12/		
Events to Avert	423	Current Ra (12/01/2020–11/	1.48	
Mumber of Target Hospitals	53	Goal Rate	0.60	



Challenges to CLABSI Reduction

- Increased patient acuity
- Increased length of inpatient stay
- Increased device utilization
- Staffing concerns

- Bundle compliance
- Resource availability
- Staff burnout
- What must be done versus what should be done (drift)



CLABSI Reduction Efforts During the COVID-19 Pandemic


Caroline Gill Rifold, RN, BSN Manager, Infection Prevention CHA Hollywood Presbyterian Medical

Center – Los Angeles, CA





HSAG HQIC TAP Strategy






HSAG HQIC CLABSI Audit Tool

lafa dian Duana dian	ate: Patient Census: . Jnit: Number of Patients with Devices:					
Infection Prevention	omplete for each Central Line in use: COMMENTS	Central Line 1	Central Line 2	Central Line 3		
CAUTI	irect Observation ROOM #					
CLABSI	 Are hand hygiene stations and supplies readily available? Is the central line secured via an occlusive dressing and has the dressing been changed per facility policy? 	Yes	Yes No	Yes		
CLABSI	3. Are antibacterial caps in place per facility policy?	Yes	Yes	No		
	4. Is the IV tubing dated/timed/initialed per facility policy?	No	Yes	Yes		
Central Line-Associated Bloodstream Infe	5. Is the IV solution dated/timed/initialed per facility policy?	Yes	Yes	Yes		
Target	 Is the tubing capped if not in use? Has the patient been educated regarding appropriate 	No	No	Yes		
CLABSI Targeted Assessment for Prevention (TAP) Framework	central line care and what to do if he/she notices a concern?	Yes	Yes	Yes		
• TAP Strategy (PDF)	Total Positive Per Patient Total % Adherence Per Patient	5 71.4%	5 71.4%	6 85.7%		
Assess • CLABSI Audit Tool (Excel download) Contact your Quality Advisor for these tools: • CLABSI Exploration Form • CLABSI Tracer Tool	 hart Review 8. Is there documentation indicating which department inserted the central line? 8a. Note the department/unit where the central line was inserted 9. Does documentation support central line placement? 10. Is there documentation available for completion of the insertion bundle checklist? 11. Has there been a check for central line necessity today? 	Yes Emergency Department Yes Yes Yes Hemodynamic	No Emergency Department Yes No Yes volumes of fluids	Yes ICU Yes Yes No		
Prevent	12. What criterion is noted?	monitoring	including blood or blood	No indication		
 CLABSI Implementation Guide An online guide from the Ager CLABSI Prevention Checklist From the Centers for Disease 0 	13. Comments					
	Total Positive Per Patient Total % Adherence Per Patient	4 100.0%	2 50.0%	3 75.0%		



HSAG HQIC CLABSI Audit Tool (cont.)





HSAG HQIC CLABSI Exploration Tool

Central Line-Associated Bloodstream	Infection (CLABSI): Exploration Form			
Complete this form for every CLABSI by reviewing the patien the patient or central line. As you answer the questions, ren	nember to ask "why?" when seeking an explanation. The	HSAG HOIC		
investigation should begin as soon as the diagnosis is made a ensure that clinicians clearly remember the events that may		What was documented about the central line insertion?		
Date(s) of investigation: Person(s) conducting investigati	on:			
Patient initials: Age: Medical record #	MaleFemale	Interview at least one person who was present during the insertion. Is there additional information about the insertion process that was not included in the documentation? Y N If yes, describe:		
Hawaiian/Pacific Islander □ White □ Not indicated in pa record				
Admit date: Adm	nitting diagnosis:	In the 72 hours prior to the CLABSI, did the patient receive a bath at least once every 24 hours? Y N bath?		
Discharge date: Was the patient discharged alive? Y N If no, list t Was the patient transferred from one location to another wi		In the 72 hours prior to the CLABSI, is there documentation by a physician at least once every 24 hours, of the reason for the continued use of the central line?YN		
prior to the infection? YN If yes, describe:		In the 72 hours prior to the CLABSI, is there documentation by a nurse at least once every 24 hours, of the reason for the continued use of the central line? YN		
What co-morbidities or patient factors may have contributed infections, hyperglycemia, obesity, or agitation)?	d to the CLABSI (e.g., traumatic insertion, concurrent	On the unit where the patient was located at the time of the CLABSI, is there a process that includes observation of the central line by the charge nurse or another person? Y _ N		
Who inserted the central line prior to the CLABSI:		If yes, what date(s) prior to the CLABSI was the central line observed?		
Was the patient intubated prior to the infection or at the time of insertion?	If yes, what were the dates the patient was intubated?	Were there any deficiencies in any observations prior to the CLABSI? YN If yes, what deficiencies occurred?		
Was the patient in isolation prior to the central line being inserted during this admission?	If yes, why was the patient in isolation?	Were there any events occurring on the unit at the time of the insertion that may have affected the clinician's ability to		
Where on the patient's body was the central line inserted? Where in the hospital was the central line inserted?		insert the central line?YN If yes, describe:		
What was the indication for the central line?				
Prior to infection, when was the central line inserted (date/time)?	Was this insertion a re-insertion?	Were any concerns or issues related to the central line insertion equipment or supplies identified during this investigation?		
When was the positive blood culture obtained (date/time)?	What organism(s) were identified in the positive blood culture?	If yes, please describe: What have you done to ensure that the next patient with a central line will be safe from acquiring an infection at your		
How many days was the central line in place prior to the dat	e of a positive blood culture?	hospital?		
If the infection occurred within 3 days of insertion, were any (CLIP) form?YN If yes, what was missing?	elements missing on the central line insertion practice			



HSAG HQIC SUR Calculator

Hospital Type	Measure Type	Unit Type (CDC Location Code)*	Facility Size	Teaching Status	Observed Device Days	Observed Patient Days	Predicted Device Days	SUR
cute Care Hospitals	CLABSI	Critical Care Units	≥ 268 beds	Major	327	568	309.886	1.055
eference 'CDC Location Code' shee	t for a breakout of CDC Location C	ode						
	Acute Care Hos	pitals CLABSI			Acute Ca	are Hospitals CAU	ודנ	
CDC Location Name: Cr	itical Care Units			CDC Location Nam	e: Adult Critical Care	2		
Burn Critical C	are				ardiothoracic Critic	_		
Medical Cardi	ac Critical Care			_	ritical Care			
Surgical Cardi	othoracic Critical Care			Medical S	urgical Critical Care			
Medical Critic	al Care				Critical Care			
Medical Surgio	cal Critical Care				ical Critical Care			
Neurology Crit					, Medical Critical Car	e		
Neurosurgical					Oncology Critical Ca			
	ical Critical Care				Surgical Critical Car			
	ical Surgical Critical Ca	re			ritical Care	-		
-	ology Critical Care				itical Care			
Prenatal Critic	ical Critical Care				e: Pediatric Critical	Care		
Respiratory Cr					Burn Critical Care	<u>cure</u>		
Surgical Critic					Surgical Cardiothora	acic Critical Care		
Trauma Critica					Medical Surgical Cri			
	diatric Critical Care Uni	its			Neurosurgical Critic			
Pediatric Burn					Surgical Care	a. care		
Pediatric Card	iothoracic Critical Care				Frauma Critical Care	2		
Pediatric Med	ical Surgical Critical Ca	re			e: Burn and Cardiac	-		
Pediatric Med	ical Critical Care			Burn Critic		entited one		





Thank you!

Eli DeLille, MSN, RN, CIC, FAPIC

Associate Director HSAG Infection Preventionist edelille@hsag.com **Geoff Granseth, MPH, CIC** Quality Advisor HSAG Infection Preventionist ggranseth@hsag.com

This material was prepared by Health Services Advisory Group (HSAG), a Hospital Quality Improvement Contractor (HQIC) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. XS-HQIC-IP-04052022-01

Discussion

- What information can you leverage to help expand opportunities in your facilities and communities?
- What impactful actions can you take as a result of the information shared today?
- Where can you begin with your facility to continue to ensure safety, and a true patient-centered approach as you engage collaboratively with others?
- What activities do you have underway that will allow for you to expand and push forward in action over the next 30, 60 or 90 days?

Final Thoughts



Join Us for the Next Community of Practice Call!

Join us for the next Community of Practice Call on June 9, 2022 from 1:00 – 2:00 PM ET

We invite you to register at the following link:

https://zoom.us/webinar/register/WN ASI I3p TEyx VY YYFFeA

You will receive a confirmation email with login details.



Thank You!



Your opinion is valuable to us. Please take 4 minutes to complete the post event assessment here: <u>post assessment 5.12.22</u>

We will use the information you provide to improve future events.

